Mohamed W Attwa

List of Publications by Citations

68 papers	764 citations	18 h-index	24 g-index
71 ext. papers	931 ext. citations	3.3 avg, IF	4.81 L-index

#	Paper	IF	Citations
68	Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling. *Drug Design, Development and Therapy*, **2017**, 11, 2333-2346	4.4	37
67	Reactive intermediates and bioactivation pathways characterization of avitinib by LC-MS/MS: In vitro metabolic investigation. *Journal of Pharmaceutical and Biomedical Analysis*, **2019**, 164, 659-667	3.5	34
66	Identification and characterization of in vitro phase I and reactive metabolites of masitinib using a LC-MS/MS method: bioactivation pathway elucidation. *RSC Advances*, **2017**, 7, 4479-4491	3.7	33
65	LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation. *Journal of Pharmaceutical and Biomedical Analysis*, **2018**, 160, 19-30	3.5	32
64	An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma. *Biomedical Chromatography*, **2017**, 31, e3793	1.7	31
63	Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways. *RSC Advances*, **2016**, 6, 72575-72585	3.7	29
62	Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC-ESI-MS/MS. *Chemistry Central Journal*, **2018**, 12, 99		29
61	A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study. *Biomedical Chromatography*, **2016**, 30, 1248-55	1.7	26
60	Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry. *Clinica Chimica Acta*, **2018**, 480, 180-185	6.2	25
59	LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways.. *RSC Advances*, **2018**, 8, 1182-1190	3.7	25
58	A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate. *European Journal of Mass Spectrometry*, **2018**, 24, 344-351	1.1	24
57	LC-MS/MS reveals the formation of reactive ortho-quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling. *Clinica Chimica Acta*, **2018**, 482, 84-94	6.2	24
56	LC-MS/MS reveals the formation of aldehydes and iminium reactive intermediates in foretinib metabolism: phase I metabolic profiling. *RSC Advances*, **2017**, 7, 36279-36287	3.7	24
55	Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability. *PLoS ONE*, **2016**, 11, e0164967	3.7	24
54	Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation. *Chemistry Central Journal*, **2017**, 11, 45		22
53	Detection and characterization of olmutinib reactive metabolites by LC-MS/MS: Elucidation of bioactivation pathways. *Journal of Separation Science*, **2020**, 43, 708-718	3.4	22
52	Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies. *Drug Design, Development and Therapy*, **2020**, 14, 783-793	4.4	18

51	Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation and toxicity studies of its metabolites.. *RSC Advances*, **2020**, 10, 5412-5427	3.7	18
50	Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma.. *RSC Advances*, **2018**, 8, 40387-40394	3.7	18
49	Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS. *Clinica Chimica Acta*, **2018**, 485, 298-304	6.2	17
48	Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine. *Tropical Journal of Pharmaceutical Research*, **2017**, 15, 2683	0.8	16
47	Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC-MS/MS: metabolic investigation. *Royal Society Open Science*, **2019**, 6, 181714	3.3	14
46	A simple liquid chromatography-tandem mass spectrometry method to accurately determine the novel third-generation EGFR-TKI naquotinib with its applicability to metabolic stability assessment.. *RSC Advances*, **2019**, 9, 4862-4869	3.7	13
45	LC-MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate. *Chemistry Central Journal*, **2017**, 11, 136		13
44	High Throughput Quantitative Bioanalytical LC/MS/MS Determination of Gemifloxacin in Human Urine. *Journal of Chemistry*, **2013**, 2013, 1-9	2.3	13
43	Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability. *PLoS ONE*, **2019**, 14, e0214598	3.7	12
42	Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: phase I metabolic investigation.. *RSC Advances*, **2018**, 8, 38733-38744	3.7	11
41	and metabolism of ribociclib: a mass spectrometric approach to bioactivation pathway elucidation and metabolite profiling.. *RSC Advances*, **2020**, 10, 22668-22683	3.7	10
40	Rapid validated liquid chromatographic method coupled with Tandem mass spectrometry for quantification of nintedanib in human plasma. *Tropical Journal of Pharmaceutical Research*, **2016**, 15, 2467	0.8	10
39	A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation. *Royal Society Open Science*, **2019**, 6, 190434	3.3	9
38	Belizatinib: Novel reactive intermediates and bioactivation pathways characterized by LC-MS/MS. *Journal of Pharmaceutical and Biomedical Analysis*, **2019**, 171, 132-147	3.5	9
37	Identification and characterization of , , , and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and toxicity studies of its metabolites.. *RSC Advances*, **2020**, 10, 16231-16244	3.7	9
36	Microwave-assisted solution-phase synthesis and DART-mass spectrometric monitoring of a combinatorial library of indolin-2,3-dione schiff bases with potential antimycobacterial activity. *Molecules*, **2011**, 16, 5194-206	4.8	9
35	EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation: and Rat Studies. *Chemical Research in Toxicology*, **2020**, 33, 1719-1728	4	7
34	A preliminary study of arecoline and guvacoline presence in the saliva of a "betel-quid" chewer using liquid-chromatography ion trap mass spectrometry. *European Journal of Mass Spectrometry*, **2013**, 19, 391-7	1.1	7

33	Induced in-source fragmentation pattern of certain novel (1Z,2E)-N-(aryl)propanehydrazonoyl chlorides by electrospray mass spectrometry (ESI-MS/MS). *Chemistry Central Journal*, **2013**, 7, 16		6
32	LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2021**, 1179, 122806	3.2	6
31	Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation.. *RSC Advances*, **2019**, 9, 19323-19332	3.7	5
30	Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2020**, 1154, 122195	3.2	5
29	Exploring the effect of khat (Catha edulis) chewing on the pharmacokinetics of the antiplatelet drug clopidogrel in rats using the newly developed LC-MS/MS technique. *Open Chemistry*, **2020**, 18, 681-690	1.6	5
28	Fragmentation Behavior Studies of Chalcones Employing Direct Analysis in Real Time (DART). *Mass Spectrometry Letters*, **2013**, 4, 30-33		5
27	Development and validation of HPLC-MS/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study. *Biomedical Chromatography*, **2017**, 31, e4007	1.7	4
26	Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: phase I metabolic profiling.. *RSC Advances*, **2019**, 9, 6409-6418	3.7	4
25	Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation. *Molecules*, **2020**, 25,	4.8	4
24	Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry. *Chemistry Central Journal*, **2018**, 12, 61		4
23	Effective quantification of ravidasvir (an NS5A inhibitor) and sofosbuvir in rat plasma by validated LC-MS/MS method and its application to pharmacokinetic study. *Arabian Journal of Chemistry*, **2020**, 13, 8160-8171	5.9	3
22	A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma. *Drug Design, Development and Therapy*, **2020**, 14, 407-415	4.4	3
21	Development and validation of an HPLC-MS/MS method for the determination of arginine-vasopressin receptor blocker conivaptan in human plasma and rat liver microsomes: application to a metabolic stability study. *Chemistry Central Journal*, **2018**, 12, 47		3
20	Liquid chromatography-tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites. *Royal Society Open Science*, **2019**, 6, 190852	3.3	3
19	Estimation of zorifertinib metabolic stability in human liver microsomes using LC-MS/MS.. *Journal of Pharmaceutical and Biomedical Analysis*, **2022**, 211, 114626	3.5	3
18	Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS/MS.. *RSC Advances*, **2019**, 9, 32995-33006	3.7	3
17	Simple and efficient spectroscopic-based univariate sequential methods for simultaneous quantitative analysis of vandetanib, dasatinib, and sorafenib in pharmaceutical preparations and biological fluids. *Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy*, **2021**, 260, 119987	4.4	3
16	Reactive intermediates in naquotinib metabolism identified by liquid chromatography-tandem mass spectrometry: phase I metabolic profiling.. *RSC Advances*, **2019**, 9, 10211-10225	3.7	2

15	LC-ESI-MS/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites. *Clinica Chimica Acta*, **2018**, 485, 144-151	6.2	2
14	Pseudo-MS3Approach Using Electrospray Mass Spectrometry (ESI-MS/MS) to Characterize Certain (2E)-2-[3-(1H-Imidazol-1-yl)-1-phenylpropylidene]hydrazinecarboxamide Derivatives. *Journal of Chemistry*, **2014**, 2014, 1-10	2.3	2
13	Multistage fragmentation of ion trap mass spectrometry system and pseudo-MS3 of triple quadrupole mass spectrometry characterize certain (E)-3-(dimethylamino)-1-arylprop-2-en-1-ones: a comparative study. *Scientific World Journal, The*, **2014**, 2014, 702819	2.2	2
12	LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay. *Drug Design, Development and Therapy*, **2020**, 14, 4439-4449	4.4	2
11	Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids. *Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy*, **2022**, 264, 120336	4.4	2
10	Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach. *Drug Design, Development and Therapy*, **2020**, 14, 5259-5273	4.4	1
9	Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry. *Drug Design, Development and Therapy*, **2020**, 14, 111-119	4.4	1
8	Fragmentation pattern of certain isatin□indole antiproliferative conjugates with application to identify their in vitro metabolic profiles in rat liver microsomes by liquid chromatography tandem mass spectrometry. *Open Chemistry*, **2020**, 18, 503-515	1.6	1
7	Spectroscopic, molecular docking and dynamic simulation studies of binding between the new anticancer agent olmutinib and human serum albumin. *Journal of Biomolecular Structure and Dynamics*, **2021**, 1-11	3.6	1
6	A Validated LC-MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation. *Molecules*, **2021**, 26,	4.8	1
5	LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation. *Drug Design, Development and Therapy*, **2021**, 15, 3915-3925	4.4	1
4	Identification and characterization of , , and reactive metabolites of tandutinib using liquid chromatography ion trap mass spectrometry. *Analytical Methods*, **2021**, 13, 399-410	3.2	1
3	Liquid chromatographic-mass spectrometric method for determination of drug content uniformity of two commonly used dermatology medications in a split-tablet dosage form. *Tropical Journal of Pharmaceutical Research*, **2016**, 15, 1283	0.8	0
2	Detection and characterization of simvastatin and its metabolites in rat tissues and biological fluids using MALDI high resolution mass spectrometry approach.. *Scientific Reports*, **2022**, 12, 4757	4.9	0
1	Lodenafil.. *Profiles of Drug Substances, Excipients and Related Methodology*, **2022**, 47, 113-147	3	